A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection

K. Kieburtz, D. Simpson, C. Yiannoutsos, M. B. Max, C. D. Hall, R. J. Ellis, C. M. Marra, R. McKendall, E. Singer, G. J. Dal Pan, D. B. Clifford, T. Tucker, B. Cohen

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Background: Painful sensory neuropathy is a common complication of HIV infection. Based on prior uncontrolled observations, we hypothesized that amitriptyline or mexiletine would improve the pain symptoms. Method: A randomized, double-blind, 10-week trial of 145 patients assigned equally to amitriptyline, mexiletine, or matching placebo. The primary outcome measure was the change in pain intensity between baseline and the final visit. Results: The improvement in amitriptyline group (0.31 ± 0.31 units [mean ± SD]) and mexiletine group (0.23 ± 0.41) was not significantly different from placebo (0.20 ± 0.30). Both interventions were generally well tolerated. Conclusions: Neither amitriptyline nor mexiletine provide significant pain relief in patients with HIV-associated painful sensory neuropathy.

Original languageEnglish (US)
Pages (from-to)1682-1688
Number of pages7
JournalNeurology
Volume51
Issue number6
StatePublished - Dec 1998

Fingerprint

Mexiletine
Amitriptyline
HIV Infections
Pain
Placebos
Outcome Assessment (Health Care)
HIV
Painful Neuropathy

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Kieburtz, K., Simpson, D., Yiannoutsos, C., Max, M. B., Hall, C. D., Ellis, R. J., ... Cohen, B. (1998). A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology, 51(6), 1682-1688.

A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. / Kieburtz, K.; Simpson, D.; Yiannoutsos, C.; Max, M. B.; Hall, C. D.; Ellis, R. J.; Marra, C. M.; McKendall, R.; Singer, E.; Dal Pan, G. J.; Clifford, D. B.; Tucker, T.; Cohen, B.

In: Neurology, Vol. 51, No. 6, 12.1998, p. 1682-1688.

Research output: Contribution to journalArticle

Kieburtz, K, Simpson, D, Yiannoutsos, C, Max, MB, Hall, CD, Ellis, RJ, Marra, CM, McKendall, R, Singer, E, Dal Pan, GJ, Clifford, DB, Tucker, T & Cohen, B 1998, 'A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection', Neurology, vol. 51, no. 6, pp. 1682-1688.
Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, Ellis RJ et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology. 1998 Dec;51(6):1682-1688.
Kieburtz, K. ; Simpson, D. ; Yiannoutsos, C. ; Max, M. B. ; Hall, C. D. ; Ellis, R. J. ; Marra, C. M. ; McKendall, R. ; Singer, E. ; Dal Pan, G. J. ; Clifford, D. B. ; Tucker, T. ; Cohen, B. / A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. In: Neurology. 1998 ; Vol. 51, No. 6. pp. 1682-1688.
@article{d80277958ad745c9a63826fb0f568e0a,
title = "A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection",
abstract = "Background: Painful sensory neuropathy is a common complication of HIV infection. Based on prior uncontrolled observations, we hypothesized that amitriptyline or mexiletine would improve the pain symptoms. Method: A randomized, double-blind, 10-week trial of 145 patients assigned equally to amitriptyline, mexiletine, or matching placebo. The primary outcome measure was the change in pain intensity between baseline and the final visit. Results: The improvement in amitriptyline group (0.31 ± 0.31 units [mean ± SD]) and mexiletine group (0.23 ± 0.41) was not significantly different from placebo (0.20 ± 0.30). Both interventions were generally well tolerated. Conclusions: Neither amitriptyline nor mexiletine provide significant pain relief in patients with HIV-associated painful sensory neuropathy.",
author = "K. Kieburtz and D. Simpson and C. Yiannoutsos and Max, {M. B.} and Hall, {C. D.} and Ellis, {R. J.} and Marra, {C. M.} and R. McKendall and E. Singer and {Dal Pan}, {G. J.} and Clifford, {D. B.} and T. Tucker and B. Cohen",
year = "1998",
month = "12",
language = "English (US)",
volume = "51",
pages = "1682--1688",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection

AU - Kieburtz, K.

AU - Simpson, D.

AU - Yiannoutsos, C.

AU - Max, M. B.

AU - Hall, C. D.

AU - Ellis, R. J.

AU - Marra, C. M.

AU - McKendall, R.

AU - Singer, E.

AU - Dal Pan, G. J.

AU - Clifford, D. B.

AU - Tucker, T.

AU - Cohen, B.

PY - 1998/12

Y1 - 1998/12

N2 - Background: Painful sensory neuropathy is a common complication of HIV infection. Based on prior uncontrolled observations, we hypothesized that amitriptyline or mexiletine would improve the pain symptoms. Method: A randomized, double-blind, 10-week trial of 145 patients assigned equally to amitriptyline, mexiletine, or matching placebo. The primary outcome measure was the change in pain intensity between baseline and the final visit. Results: The improvement in amitriptyline group (0.31 ± 0.31 units [mean ± SD]) and mexiletine group (0.23 ± 0.41) was not significantly different from placebo (0.20 ± 0.30). Both interventions were generally well tolerated. Conclusions: Neither amitriptyline nor mexiletine provide significant pain relief in patients with HIV-associated painful sensory neuropathy.

AB - Background: Painful sensory neuropathy is a common complication of HIV infection. Based on prior uncontrolled observations, we hypothesized that amitriptyline or mexiletine would improve the pain symptoms. Method: A randomized, double-blind, 10-week trial of 145 patients assigned equally to amitriptyline, mexiletine, or matching placebo. The primary outcome measure was the change in pain intensity between baseline and the final visit. Results: The improvement in amitriptyline group (0.31 ± 0.31 units [mean ± SD]) and mexiletine group (0.23 ± 0.41) was not significantly different from placebo (0.20 ± 0.30). Both interventions were generally well tolerated. Conclusions: Neither amitriptyline nor mexiletine provide significant pain relief in patients with HIV-associated painful sensory neuropathy.

UR - http://www.scopus.com/inward/record.url?scp=0031701543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031701543&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 1682

EP - 1688

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -